

SENATE, No. 2301

STATE OF NEW JERSEY

216th LEGISLATURE

INTRODUCED JULY 10, 2014

Sponsored by:

Senator LINDA R. GREENSTEIN

District 14 (Mercer and Middlesex)

Senator BRIAN P. STACK

District 33 (Hudson)

Co-Sponsored by:

Senators Connors, Oroho, Thompson, Allen, Beach and A.R.Bucco

SYNOPSIS

Regulates pharmacy benefits managers and requires certain disclosures concerning multiple source generic drug pricing.

CURRENT VERSION OF TEXT

As introduced.



(Sponsorship Updated As Of: 12/8/2015)

1 AN ACT concerning pharmacy benefits managers and
2 supplementing Title 17B of the New Jersey Statutes.

3
4 **BE IT ENACTED** *by the Senate and General Assembly of the State*
5 *of New Jersey:*

6
7 1. As used in this act:

8 "Carrier" means an insurance company, health service
9 corporation, hospital service corporation, medical service
10 corporation, or health maintenance organization authorized to issue
11 health benefits plans in this State.

12 "Covered person" means a person on whose behalf a carrier or
13 other entity, who is the sponsor of the health benefits plan, is
14 obligated to pay benefits pursuant to a health benefits plan.

15 "Drug" means a drug or device as defined in R.S.24:1-1.

16 "Health benefits plan" means a benefits plan which pays hospital
17 or medical expense benefits for covered services, or prescription
18 drug benefits for covered services, and is delivered or issued for
19 delivery in this State by or through a carrier or any other sponsor,
20 including, but not limited to, a carrier, self-insured employer, or
21 union. For the purposes of this act, health benefits plan shall not
22 include the following plans, policies or contracts: accident only,
23 credit disability, long-term care, Medicare supplement coverage;
24 CHAMPUS supplement coverage, coverage for Medicare services
25 pursuant to a contract with the United States government, coverage
26 arising out of a worker's compensation or similar law, coverage
27 under a policy of private passenger automobile insurance issued
28 pursuant to P.L.1972, c.70 (C.39:6A-1 et seq.), or hospital
29 confinement indemnity coverage.

30 "Pharmacy" means any place in the State where drugs are
31 dispensed or pharmaceutical care is provided by a licensed
32 pharmacist, but shall not include a medical office under the control
33 of a licensed physician.

34 "Pharmacy benefits manager" means a corporation, business, or
35 other entity, or unit within a corporation, business, or other entity,
36 that administers prescription drug benefits on behalf of a purchaser.

37 "Pharmacy benefits management services" means the provision
38 of any of the following services on behalf of a purchaser: the
39 procurement of prescription drugs at a negotiated rate for
40 dispensation within this State; the processing of prescription drug
41 claims; or the administration of payments related to prescription
42 drug claims.

43 "Prescription" means a prescription as defined in section 5 of
44 P.L.1977, c.240 (C.24:6E-4).

45 "Prescription drug benefits" means the benefits provided for
46 prescription drugs and pharmacy services for covered services
47 under a health benefits plan contract.

1 "Purchaser" means any sponsor of a health benefits plan who
2 enters into an agreement with a pharmacy benefits management
3 company for the provision of pharmacy benefits management
4 services to covered persons.

5
6 2. Beginning on the first day of each calendar year, a pharmacy
7 benefits manager shall, with respect to contracts between a
8 pharmacy benefits manager and a pharmacy:

9 a. (1) include in the contract the basis of the methodology and
10 sources utilized to determine multiple source generic drug pricing,
11 including, if applicable, the maximum allowable cost or any
12 successive benchmark pricing formula, of the pharmacy benefits
13 manager;

14 (2) update that pricing information each day; and

15 (3) establish a reasonable process for the prompt notification of
16 those pricing updates to network pharmacies; and

17 b. Maintain a procedure to eliminate drugs from the list of
18 drugs subject to multiple source generic drug pricing or modify
19 maximum allowable cost rates in a timely fashion.

20
21 3. In order to place a particular prescription drug on a multiple
22 source generic list, the pharmacy benefits manager shall, at a
23 minimum, ensure that:

24 a. The drug has at least three nationally available,
25 therapeutically equivalent multiple source generic drugs with a
26 significant cost difference;

27 b. The drug is listed as therapeutically and pharmaceutically
28 equivalent or "A" rated in the Food and Drug Administration's most
29 recent version of the Approved Drug Products with Therapeutic
30 Equivalence Evaluations, commonly known as the "Orange Book;"
31 and

32 c. The drug is available for purchase without limitations by all
33 pharmacies in the State from national or regional wholesalers and is
34 not obsolete or temporarily unavailable.

35
36 4. The pharmacy benefits manager shall disclose to the
37 purchaser in the contract:

38 a. the basis of the methodology and sources utilized to
39 establish multiple source generic pricing. Applicable lists shall be
40 updated and provided to the purchaser whenever there is a change;
41 and

42 b. if a pharmacy benefits manager utilizes a multiple source
43 generic list for drugs dispensed at retail, but does not utilize a
44 similar list for drugs dispensed by mail. This practice shall be
45 disclosed to the purchaser in writing either in the contract or no
46 later than 21 business days from the implementation of the practice;
47 and

1 c. whether or not the pharmacy benefits manager is using the
2 identical multiple source generic drug list with respect to billing the
3 purchaser as it does when reimbursing all network pharmacies. If
4 multiple source generic drug lists are used, the pharmacy benefits
5 manager shall disclose any difference between the amount paid to
6 any pharmacy and the amount charged to the purchaser.

7
8 5. All contracts between a pharmacy benefits manager and a
9 pharmacy shall include a process to appeal, investigate, and resolve
10 disputes regarding multiple source generic drug pricing. The
11 contract provision establishing the process shall include the
12 following:

13 a. The right to appeal shall be limited to 60 days following the
14 initial claim;

15 b. The appeal shall be investigated and resolved by the
16 pharmacy benefits manager through an internal process within
17 seven days of receipt of the appeal by the pharmacy benefits
18 manager;

19 c. A telephone number at which a pharmacy may contact the
20 pharmacy benefits manager and speak with an individual who is
21 responsible for processing appeals; and

22 d. (1) If the appeal is denied, the pharmacy benefits manager
23 shall provide the reason for the denial and identify the national drug
24 code of a drug that may be purchased by contracted pharmacies at a
25 price at or below the maximum allowable cost, or for a benchmark
26 price as shall be determined by the pharmacy benefits manager;

27 (2) If the appeal is upheld, the pharmacy benefits manager shall
28 make an adjustment retroactive to the date of adjudication. The
29 pharmacy benefits manager shall make the adjustment effective for
30 all similarly situated pharmacies in this State that are within the
31 network.

32
33 6. All contracts between a pharmacy benefits manager and a
34 pharmacy shall provide a contractual commitment to the pharmacy
35 to deliver a generic effective rate. A generic effective rate shall be
36 either:

37 a. a particular aggregate average reimbursement rate for
38 generics; or

39 b. a maximum average wholesale price discount on multiple
40 source generics as a whole.

41 For the purposes of this discount amount, a pharmacy benefits
42 manager shall utilize an average wholesale price published by a
43 nationally available compendium. The generic effective rate shall
44 be calculated using the actual amount paid to the pharmacy,
45 including pharmacy benefits manager reimbursement plus patient
46 co-pay, excluding the dispensing fee, and shall not be calculated
47 solely according to the amount allowed by the plan and shall
48 include all generics dispensed, regardless of whether they are

1 subject to any pharmacy benefits manager-determined multiple
2 source generic drug pricing.

3

4 7. The Commissioner of Banking and Insurance shall adopt,
5 pursuant to the “Administrative Procedure Act,” P.L.1968, c.410
6 (C.52:14B-1 et seq.), rules and regulations, including any penalty
7 provisions the commissioner deems to be necessary, to effectuate
8 the purposes of this act.

9

10 8. This act shall take effect on the 90th day next following
11 enactment and shall apply to all contracts or agreements for
12 pharmacy benefits management services that are executed or
13 renewed on or after the effective date.

14

15

16

STATEMENT

17

18 This bill requires pharmacy benefits managers (PBMs) to
19 disclose certain information about multiple source generic drug
20 pricing to plan sponsors and pharmacies and to deliver a particular
21 aggregate average reimbursement rate for generics.

22 With respect to pharmacies, the bill requires pharmacy benefits
23 managers to disclose the methodology and sources utilized to
24 determine multiple source generic drug pricing. That pricing
25 information is required to be updated daily and the PBM must have
26 a process for the prompt notification of those pricing updates to
27 network pharmacies. The bill also requires PBMs to maintain a
28 procedure to eliminate products from the list of drugs subject to
29 multiple source generic drug pricing or modify maximum allowable
30 cost rates in a timely fashion.

31 Further, the bill stipulates that all contracts between a PBM and a
32 pharmacy shall include a process to appeal, investigate, and resolve
33 disputes regarding multiple source generic drug pricing. The
34 contract provision establishing the process shall include the
35 following:

36 (1) The right to appeal shall be limited to 60 days following the
37 initial claim;

38 (2) The appeal shall be investigated and resolved within seven
39 days;

40 (3) A telephone number at which a pharmacy may contact the
41 pharmacy benefits manager and speak with an individual who is
42 responsible for processing appeals;

43 (4) If the appeal is denied, the pharmacy benefits manager shall
44 provide the reason for the denial and identify the national drug code
45 of a drug that may be purchased by contracted pharmacies at a price
46 at or below the maximum allowable cost, or benchmark price as
47 determined by the pharmacy benefits manager;

1 (5) If the appeal is upheld, the pharmacy benefits manager shall
2 make an adjustment retroactive to the date of adjudication. The
3 pharmacy benefits manager shall make the adjustment effective for
4 all similarly situated pharmacies in this State that are within the
5 network.

6 The bill also requires that, in order for a PBM to place a
7 particular prescription drug on a multiple source generic list, the
8 PBM must ensure that:

9 (1) The drug has at least three or more nationally available,
10 therapeutically equivalent multiple source generic drugs with a
11 significant cost difference;

12 (2) The products must be listed as therapeutically and
13 pharmaceutically equivalent or “A” rated in the Food and Drug
14 Administration’s most recent version of the Approved Drug
15 Products with Therapeutic Equivalence Evaluations, commonly
16 known as the “Orange Book;” and

17 (3) The drug must be available for purchase without limitations
18 by all pharmacies in the State from national or regional wholesalers
19 and not obsolete or temporarily unavailable.

20 With respect to the plan sponsor, the PBM is required to disclose
21 the basis of the methodology and sources utilized to establish
22 multiple source generic pricing. Applicable lists shall be updated to
23 the plan sponsor whenever there is a change. The PBM must also
24 disclose to the plan sponsor:

25 (1) if the PBM utilizes a multiple source generic list for drugs
26 dispensed at retail, but does not utilize a similar list for drugs
27 dispensed by mail;

28 (2) whether or not it is using the identical multiple source
29 generic drug list with respect to billing the plan sponsor as it does
30 when reimbursing all network pharmacies;

31 (3) if multiple source generic drug lists are used, the PBM must
32 disclose any difference between the amount paid to any pharmacy
33 and the amount charged to the plan sponsor.

34 Finally, the bill requires a PBM to provide a contractual
35 commitment to deliver a particular aggregate average
36 reimbursement rate for generics or a maximum average wholesale
37 price discount on multiple source generics as a whole, otherwise
38 referred to as a “generic effective rate.”